Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06469788 · ClinicalTrials.gov registry record · NA

Testimonials and Navigation in Rheumatology

A NA study of Autoimmune Diseases and Rheumatologic Disease, sponsored by University of Alabama at Birmingham.

Recruiting
Registry status
NA
Development phase
1,170
Enrollment target
3
Study locations

NCT06469788 is a NA study of Autoimmune Diseases and Rheumatologic Disease that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 1,170 participants, above the 932-participant average among 25 other Autoimmune Diseases trials with a reported enrollment target (26% higher). The trial reports 3 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06469788, a NA study of Autoimmune Diseases and Rheumatologic Disease, is actively recruiting participants, sponsored by University of Alabama at Birmingham.

RECRUITING
Registry status
NA
Development phase
1,170 participants
Enrollment target
3
Study locations

Study Summary

The overall goal of this study is to determine whether a novel, multi-modal, patient-directed behavioral intervention initiated in rheumatology clinics is an effective approach to improve uptake of updated COVID-19 vaccine.

Interventions

  • BEHAVIORAL Patient Navigation
  • BEHAVIORAL Video comprised of AIRD patient narratives on COVID-19 vaccination thoughts and experiences
  • BEHAVIORAL Video on the importance of good oral health for patients with AIRD
  • BEHAVIORAL Brochure on COVID-19 vaccination in AIRD patients
  • BEHAVIORAL Brochure on the importance of good oral health in AIRD patients

Study Locations (3)

Massachusetts

  • Brigham Women's Hospital - Boston
  • University of Massachusetts Chan Medical School - Worcester

Alabama

  • University of Alabama at Birmingham - Birmingham

Trial Details

FieldValue
Enrollment Target 1,170 participants
Start Date 2024-12-18
Est. Completion 2027-08-31
Phase NA

Sponsor

University of Alabama at Birmingham

1,160 total trials

What the Registry Record Tells You About NCT06469788

The ClinicalTrials.gov registry entry for NCT06469788 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 1,170 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 932-participant average among 25 other Autoimmune Diseases trials with a reported enrollment target (26% higher). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Autoimmune Diseases appearing as the primary indexed condition, and to 5 interventions - of which Patient Navigation is the first listed.

NCT06469788 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, Alabama.

Frequently Asked Questions

What is clinical trial NCT06469788 about?

NCT06469788 is a clinical study titled "Testimonials and Navigation in Rheumatology". The overall goal of this study is to determine whether a novel, multi-modal, patient-directed behavioral intervention initiated in rheumatology clinics is an effective approach to improve uptake of updated COVID-19 vaccine.

What is the current status of trial NCT06469788?

This trial is currently recruiting. It is a NA study. The enrollment target is 1,170 participants. The study started on 2024-12-18. Estimated completion is 2027-08-31.

What conditions does trial NCT06469788 study?

This clinical trial studies the following conditions: Autoimmune Diseases, Rheumatologic Disease.

What interventions are being tested in trial NCT06469788?

The interventions under investigation include: Patient Navigation (BEHAVIORAL), Video comprised of AIRD patient narratives on COVID-19 vaccination thoughts and experiences (BEHAVIORAL), Video on the importance of good oral health for patients with AIRD (BEHAVIORAL), Brochure on COVID-19 vaccination in AIRD patients (BEHAVIORAL), Brochure on the importance of good oral health in AIRD patients (BEHAVIORAL).

Who is sponsoring clinical trial NCT06469788?

This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06469788 being conducted?

This trial has 3 study locations across Alabama, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Autoimmune Diseases

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.